Review Article
Volume 9 Issue 3 - 2020
Treatment of Covid-19 Infection. A Rationale for Current and Future Pharmacological Approach
Dimitar Popov*
Pulmonologist, Clinique Joseph Madec, Le Havre, France
*Corresponding Author: Dimitar Popov, Pulmonologist, Clinique Joseph Madec, Le Havre, France.
Received: March 02, 2020; Published: March 23, 2020




Abstract

Global efforts at this time are focused concurrently on containing interhuman spread of this virus and mitigating the impact of this virus. Treatments exist. Health officials from WHO have noted that Remdesivir has demonstrated efficacy in treating the coronavirus infection. The US commenced clinical trials in humans at to test the safety and efficacy of the drug. The first patient to be administered the drug is an evacuee from the Diamond Princess cruise ship. The National Medical Products Administration of China has approved the use of, an anti-viral drugs, as a treatment for coronavirus. Favilavir and Umifenovir are approved for marketing in the treatment of influenza and is one of the four drugs showing efficacy against the coronavirus in human trials. The other three are Chloroquine, Remdesivir and Lopinavir. The medicines were widely used to treat patients who showed resistance to Tamiflu and Relenza Rotadisk, both of which are medications used to treat and prevent influenza caused by influenza A and B viruses. Favilavir (Avigan) has been adopted by both Japan and China as an experimental drug to treat patients suffering from severe COVID-19. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro and in latest clinical trials. [6,13,14]. Already existing antiretroviral Protease Inhibitors might be also effective in this situation. A HIV protease inhibitor, Lopinavir is being studied along with Ritonavir for the treatment of MERS and SARS coronaviruses. The repurposed drug is already approved for the treatment of HIV infection under the trade name Kaletra. The combination is listed in the WHO list of essential medicines. Lopinavir is believed to act on the intracellular processes of coronavirus replication and demonstrated reduced mortality in the non-human primates (NHP) model of the MERS. Umifenovir (Arbidol) is used primarily as an antiviral treatment for influenza, similarly to Tamiflu, but also showed anti-coronavirus activity. Its use is only in China and Russia, since not approved by neither the FDA nor the EMA.

Keywords: COVID-19 Infection; Remdesivir; Favilavir; Umifenovir

References

  1. Paules CI., et al. "Coronavirus Infections-More Than Just the Common Cold". Journal of the American Medical Association (2020). 
  2. Chu CM., et al. "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings". Thorax 59.3 (2004): 252-256.
  3. Andersen PI., et al. "Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents". International Journal of Infectious Diseases 93 (2019): 268-276. 
  4. Duddu Praveen. "Coronavirus outbreak: Top coronavirus drugs and vaccines in development". Clinical Trials Arena (2020). 
  5. Crutchley RD., et al. “Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection”. HIV AIDS 8 (2016): 47-65.
  6. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends 14.1 (2020): 72-73.
  7. Nanshan Chen., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. The Lancet 395.10223 (2020): 507-513.
  8. Wang D., et al. “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. Journal of the American Medical Association (2020).
  9. NIH clinical trial of remdesivir to treat COVID-19 begins.
  10. Manli Wang., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research 30 (2020): 269-271.
  11. Emmie de Wit., et al. “Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection”. PNAS (Proceedings of the National Academy of Sciences) (2020). 
  12. Gilead launches remdesivir’s Phase III trials in Covid-19 patients (2020). 
  13. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research 30.3 (2020): 269-271.
  14. Praveen Duddu. “Coronavirus treatment: Vaccines/drugs in the pipeline for Covid-19”. 
  15. Coronavirus Disease 2019 (COVID-19) Situation Summary. 
  16. Tao Ai., et al. “Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases”. Radiology (2020). 
  17. Xiaobo Yang., et al. “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study”. The Lancet (2020).
  18. Pécheur EI., et al. "The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses". Journal of Virology 90.6 (2016): 3086-3092.
  19. Xu X-W., et al. “Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series”. British Medical Journal 368 (2020): m606.
  20. Jesús Villar. “Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial”. The Lancet 8.3 (2020): 267-276.
  21. “Drugs previously in development for SARS could be effective for COVID-19”. Medical Express (2020).
  22. Hofmann H., et al. “Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor”. Biochemical and Biophysical Research Communications 319.4 (2004): 1216- 1221.
  23. Li W., et al. “The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2”. Virology 367.2 (2007): 367-374.
  24. Catherine Offord. How COVID-19 Is Spread. 
  25. Yanan Cao. “Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations”. Nature 6 (2020): 11. 
  26. Qureshi A., et al. “A review on current status of antiviral siRNA”. Reviews in Medical Virology 28.4 (2018): e1976.
  27. APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China (2020). 
  28. La Cina approva l’uso di tocilizumab contro le complicanze del coronavirus (2020).
  29. Ying-Ying Zheng and Yi-Tong Ma. “COVID-19 and the cardiovascular system”. Nature Reviews Cardiology (2020).
  30. NIH Clinical Trial of Remdesivir to Treat COVID-19 Begins. 
  31. Chih-Cheng., et al. “Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): Facts and myths”. Journal of Microbiology, Immunology and Infection (2020).
  32. Denis Kainov. Medical News Today.
  33. Coronavirus Treatment Could Lie in Existing Drugs.
  34. Jean-Marc Rolain., et al. “Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century”. International Journal of Antimicrobial Agents 30.4 (2007): 297-308.
  35. Sheahan TP., et al. “Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV”. Nature Communications 11.1 (2020): 222. 
  36. Philippe Colson., et al. “Chloroquine and hydroxychloroquine as available weapons to fight COVID-19”. International Journal of Antimicrobial Agents 4 (2020): 105932. 
  37. COVID-19 Patients in Japan Improved on Plaquenil. 
  38. Coronavirus Drug Research: German Researchers Identify Japanese Drug, Camostat Mesylate That Could Be Repurposed to Treat Covid-19. 
  39. Markus Hoffmann. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell (2020). 
  40. Xueting Yao and Fei Ye. “In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”. Clinical Infectious Diseases (2020).
  41. Bioworld.com. COVID-19 drug development continues to surge. 
  42. Roche wins approval for Actemra for coronavirus complications. 
  43. Canna Scott W. "Making Sense of the Cytokine Storm". Pediatric Clinics of North America 59.2 (2012): 329-344. 
  44. Olumiant: EPAR - Product Information (PDF). European Medicines Agency (2017). 
  45. Richardson P., et al. "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". The Lancet 395.10223 (2020): e30-e31. 
  46. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 395.10224 (2020): 565-574. 
  47. Zhang C., et al. “Ifenprodil and Flavopiridol Identified by Genome wide RNA Interference Screening as Effective Drugs to Ameliorate Murine Acute Lung Injury after Influenza A H5N1 Virus Infection”. mSystems 4.6 (2019): e00431.
  48. Q BioMed partner Mannin Research developing potential treatment for patients infected with coronavirus and other infectious diseases. Q BioMed (2020).
  49. AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19. AIM ImmunoTech (2020).
  50. Silvio A Ñamendys-Silva. “Respiratory support for patients with COVID-19 infection”. The Lancet (2020).
  51. Philippe Gautret, Didier Raoult. "Hydroxychoroquine and Azithromycin as a treatment of COVID-19: results of an open label non randomized clinical trial". International Journal opf Antimicrobial Agents. (2020).
  52. Li WenShena ,WenZhang. “TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections”. https://doi. org/10.1016/j.biochi.2017.07.016. (2020).
  53. Yufang Shi., et al. “Nature Cell Death & Differentiation (2020) COVID-19 infection: the perspectives on immune responses. (2020).
  54. Cairns JA., et al. “Intravenous hyaluronidase therapy for myocardial infarction in man: double-blind trial to assess infarct size limitation. Circulation”. 65.4 (1982):764–771. (2020).
Citation: Dimitar Popov. “Treatment of Covid-19 Infection. A Rationale for Current and Future Pharmacological Approach". EC Pulmonology and Respiratory Medicine 9.4 (2020): 38-58.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for October Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the November issue of respective journals. Submissions are accepted on/before October 07, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk